drugset / Trial / NCT04334915
Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the effects of cenicriviroc mesylate (CVC) on arterial inflammation in people living with HIV.
Timeline
- Start
- 2022-11-22
- Primary completion
- 2024-08-15
- Completion
- 2024-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cenicriviroc | Small molecule | 150 mg | Oral |
| Subject | Cenicriviroc | Small molecule | 300 mg | Oral |